CVAC
CureVac N.V.
Company Overview
| Mkt Cap | $1.15B | Price | $5.05 |
| Volume | 644.43K | Change | -1.37% |
| P/E Ratio | 7.1 | Open | $5.12 |
| Revenue | $535.2M | Prev Close | $5.12 |
| Net Income | $162.2M | 52W Range | $2.48 - $5.72 |
| Div Yield | N/A | Target | $5.32 |
| Overall | 29 | Value | -- |
| Quality | 31 | Technical | 27 |
No chart data available
About CureVac N.V.
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Latest News
CureVac Shareholders Approve BioNTech Exchange Offer
CureVac Reports Q3 2025 Financial Results and Updates
CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CVAC | $5.05 | -1.4% | 644.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |